PT-141 20
PT-141 (bremelanotide), 20 mg per click pen, studied in libido and arousal research. Each click delivers 67 µg from a 3 mL · 300-click pen.
how many clicks
for your dose?
This PT-141 20 pen holds 20 mg across 300 clicks, so each click delivers 67 µg. Tap a dose or turn the dial; we'll count the clicks. For research reference only.
why researchers chose this pen
chose it for the click dosing, no syringes, no unit maths.
verified purity, checked against the public CoA before first use.
precise clicks in every 3 mL pen, the whole protocol in one barrel.
re-order or refer a colleague within three months.
about the
PT-141 20 pen
PT-141 (bremelanotide) is a melanocortin receptor agonist, supplied in a 3 mL / 300-click pen for research.
Certificate of analysiswhy a pen beats
a vial & syringe
Traditional research peptides arrive as lyophilised powder that must be reconstituted, drawn into insulin syringes, and converted from milligrams to units by hand, every step a chance for a dosing error.
A multi-dose pen removes the whole failure chain. The peptide arrives already dissolved and calibrated. Attach a fresh needle, turn the dial until you count your clicks, and you're done, the same audible-click mechanism trusted in insulin and GLP-1 pens worldwide.
Pens travel and store better, too: no open vials, no bent needles, no septum contamination after repeated draws. One sealed barrel, ten sterile needles, one dosing card.
how to buy
peptides safely
The peptide market has a purity problem: independent surveys routinely find underdosed, mislabelled or contaminated product sold online. The only reliable defence is third-party verification you can check yourself, not a supplier's own claims.
Before buying any peptide pen, ask three questions. Is every batch tested by an independent lab? Is the certificate of analysis available, so you can check your exact lot before first use? And does it ship cold-chain, insulated and gel-packed, so what was tested is what arrives?
Veyvora answers yes on every order, independent assay, a CoA on request against the batch number, and cold dispatch within 24 hours, paperwork packed inside.
pairs well with
view all
Overview
Veyvora’s PT-141 20 mg research pen supplies bremelanotide in a multi-dose format for controlled in-vitro laboratory work. This page covers what the pen contains and how its specification is documented, what batch-level evidence to request before purchase, and which legal and regulatory obligations apply to UK research buyers. Current GBP pricing and live stock status are confirmed at checkout. To proceed directly to the product listing, use the Purchase PT-141 button on the Veyvora product page.
Bremelanotide is a synthetic cyclic heptapeptide that acts as a melanocortin-receptor agonist, specifically at MC4R (melanocortin 4 receptor), and reached clinical development as the basis for Vyleesi, a 1.75 mg subcutaneous autoinjector the US Food and Drug Administration (FDA) approved on 21 June 2019 [1]. The Veyvora research pen is a distinct, unlicensed preparation supplied solely for in-vitro research and carries no equivalence to that licensed medicine.
Every batch is verified by two independent laboratories using high-performance liquid chromatography (HPLC), mass spectrometry and an endotoxin assay, with a public certificate of analysis (CoA) available for batch-level confirmation (Veyvora product specification, accessed 2026). That documentation chain, rather than marketing copy, is what researchers should weigh when evaluating this product.
Key Takeaways
- The pen contains 20 mg bremelanotide in a 3 mL multi-dose device delivering approximately 67 µg per click across 300 clicks.
- Batch-level CoAs verified by HPLC, mass spectrometry and endotoxin assay are publicly available; confirm the batch identifier and laboratory name before purchase.
- The product is supplied for in-vitro research only; UK buyers must hold appropriate ethics approvals and COSHH assessments before ordering.
- Pricing, VAT treatment, stock status and territory eligibility must be confirmed directly on the Veyvora product page at the point of purchase.
Product Identity and Scope
Veyvora’s PT-141 20 mg research pen contains bremelanotide, a synthetic cyclic heptapeptide melanocortin-receptor agonist with primary affinity for MC4R, supplied as a multi-dose pen format for controlled in-vitro laboratory use only. The pen delivers 20 mg of bremelanotide across 300 clicks in a 3 mL multi-dose device, with each click stated to release approximately 67 µg, based on Veyvora’s 2026 product specification.
Bremelanotide reached clinical authorisation as Vyleesi, a 1.75 mg subcutaneous autoinjector the US FDA approved on 21 June 2019 [1]. The Veyvora research pen is a distinct, unlicensed preparation that carries no equivalence to Vyleesi and must not be interpreted as a licensed medicine or a treatment for any condition.
Researchers evaluating this product should confirm the labelled quantity, batch number and CoA against the current product listing before purchase.
Verified Specifications
The pen is stated to contain 20 mg of bremelanotide in a 3 mL multi-dose format, delivering approximately 67 µg per click across 300 clicks, based on Veyvora’s 2026 product specification. These figures are drawn from the supplier’s own product listing and are not independently verified analytical results.
The table below presents the specification as stated by Veyvora. Values marked [confirm with operator] were not retrievable from a verified live source at time of writing and must be confirmed directly against the current product page or batch certificate before purchase.
| Parameter | Stated value | Source |
|---|---|---|
| Active substance | Bremelanotide (PT-141) | Veyvora 2026 product listing |
| Total content per pen | 20 mg | Veyvora 2026 product listing |
| Fill volume | 3 mL | Veyvora 2026 product listing |
| Clicks per pen | 300 | Veyvora 2026 product listing |
| Dose per click | ~67 µg | Veyvora 2026 product listing |
| Solvent / excipients | [confirm with operator] | — |
| Needle gauge | [confirm with operator] | — |
| Stated purity | [confirm with operator] | — |
The licensed US comparator, Vyleesi, is specified as 1.75 mg bremelanotide in 0.3 mL as a single-dose autoinjector [1], a distinct, FDA-authorised product whose specification must not be applied to the Veyvora research pen. Researchers should cross-reference the current listing against the batch certificate before committing to a purchase. For research-peptide storage guidance that accompanies these specifications, see Veyvora’s handling page.
Batch Documentation and Analytical Evidence
A CoA is only evidential for the specific batch it names: the document must state the batch identifier, test date, analytical method and the name of the testing laboratory before it can verify the pen in hand. Veyvora states that every batch is checked by two independent laboratories using HPLC, mass spectrometry and endotoxin assay, with a public CoA available for batch verification (Veyvora 2026 product positioning). That statement is the supplier’s own claim; no Veyvora CoA, chromatogram or third-party laboratory report was inspected in preparing this page, so supplier marketing copy does not constitute independent evidence of quality.
What a CoA Can and Cannot Prove
HPLC purity confirms the proportion of the target compound relative to detectable peaks under the conditions used; it does not confirm the absence of all possible impurities, nor does it validate the device’s dose-delivery accuracy. Mass spectrometry confirms molecular identity, and endotoxin assay addresses one category of biological contamination, but no single test covers every quality dimension. For a plain-language account of what HPLC purity figures do and do not establish, see what HPLC purity does and does not prove.
Community posts and CoAs from other vendors are not proof of this batch’s quality. Where a testing laboratory claims UKAS (United Kingdom Accreditation Service) accreditation, verify that status directly on the UKAS public register rather than through merchant copy.
Handling and Storage
No Veyvora-specific storage label, in-use instructions or batch-level temperature logger record was available for verification in preparing this page; confirm the figures below against the current Veyvora product page or the CoA supplied with your order before use.
Peptide solutions are sensitive to light, heat and repeated freeze–thaw cycles, all of which degrade the analyte by breaking peptide bonds and promoting aggregation. Veyvora states that PT-141 pens are dispatched in insulated, gel-packed 2–8 °C mailers fitted with a temperature indicator strip, and that dispatch occurs within 24 hours of order (Veyvora 2026 product positioning). That statement is the supplier’s own claim and is not independently verified cold-chain data; a generic shipping description is not a substitute for a batch-specific logger record.
The licensed US comparator, Vyleesi (bremelanotide 1.75 mg subcutaneous autoinjector), carries its own FDA-approved storage conditions [1]. Those conditions apply to a different formulation and device and must not be transferred to a Veyvora research pen.
For confirmed handling protocols once your pen arrives, see Veyvora’s research-peptide storage guidance.
Ordering Information
Current GBP pricing, stock status, available pack sizes, VAT treatment, courier details, and territory restrictions for the Veyvora PT-141 20 mg research pen were not retrieved from a verified live page capture in preparing this article. Take those figures directly from the current Veyvora product page at the point of purchase, not from third-party listings or aggregator sites.
What to Confirm Before Placing an Order
Before completing a purchase, verify the following directly with Veyvora:
- Current £ price and whether VAT is included or added at checkout
- Available pack sizes and any minimum order quantity for distributor accounts
- Stock availability and estimated dispatch lead time
- Delivery territory: whether Veyvora ships to your specific UK postcode or institution
- Invoice wording: confirm the invoice carries no medicinal claims and reflects research-only supply
Legal Sale Channel
Veyvora positions PT-141 pens as research-use-only reagents, not as medicines. Under the Human Medicines Regulations 2012, supplying a product with a medicinal presentation to UK buyers without an MHRA (Medicines and Healthcare products Regulatory Agency) marketing authorisation risks constituting unlicensed supply [4]. Confirm that the invoice and accompanying documentation reflect a research-only transaction before ordering.
Research-Use-Only Limitations
The Veyvora PT-141 20 mg research pen is supplied strictly for in-vitro laboratory research and is not presented as a prescription product, treatment, or patient-facing medicine. Under the Human Medicines Regulations 2012, any product presented as treating, preventing, or modifying physiological function in humans is classified as a medicine; supplying such a product without an MHRA marketing authorisation constitutes unlicensed supply [4]. A “research use only” label does not override presentation: product copy that includes dosage guidance, injection instructions, or sexual-function claims risks triggering that classification regardless of the disclaimer [5].
Buyers retain responsibility for their own ethics approvals, Control of Substances Hazardous to Health (COSHH) risk assessments, and any import controls applicable to their institution. Distributors reselling to academic or commercial laboratories take on separate obligations under medicines wholesale law and should seek independent legal advice before reselling [6]. Bremelanotide’s UK marketing authorisation status should be confirmed against the MHRA register on the date of purchase, as regulatory positions can change; this page could not verify that status from primary MHRA records as of 2026 [unverified].
Related Research and Comparison Pages
The pages below extend specific claims made on this product page without importing their conclusions into the purchase offer itself.
For a step-by-step process of matching a batch certificate to the pen you receive, see how to match a CoA to your pen, covering batch ID, test date, and laboratory name against the document Veyvora supplies. For a clear account of what HPLC purity figures confirm and where that method’s limits lie, what HPLC purity does and does not prove covers the analytical boundaries without overstating the result.
Bremelanotide’s only widely authorised finished medicine is Vyleesi, which the US FDA approved on 21 June 2019 as a 1.75 mg subcutaneous autoinjector [1]. That US label is not a specification for any unlicensed research pen and must not be read as one. UK and EU marketing authorisation status should be confirmed against the MHRA and European Medicines Agency (EMA) registers on the date of purchase, as that status was not verified from primary records for this page as of 2026 [unverified].
To place an order for the PT-141 20 mg research pen, visit Veyvora’s research-peptide catalogue directly and confirm current pricing, stock, and territory eligibility before proceeding.
Sources
[1] accessdata.fda.gov, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf [4] The Human Medicines Regulations 2012, regulation 46 (requirement for authorisation), legislation.gov.uk, https://www.legislation.gov.uk/uksi/2012/1916/regulation/46 [5] The Human Medicines Regulations 2012, regulation 2 (definition of a medicinal product by presentation and function), legislation.gov.uk, https://www.legislation.gov.uk/uksi/2012/1916/regulation/2 [6] The Human Medicines Regulations 2012, regulation 18 (wholesale dealing in medicinal products), legislation.gov.uk, https://www.legislation.gov.uk/uksi/2012/1916/regulation/18
